Smart Immune’s Path To Unlocking The Underappreciated Thymus

ProTcells Can Be Differentiated In Just Seven Days

French-founded biotech Smart Immune has made significant headway in stimulating the thymus, a small gland with a huge immunological impact which rarely finds itself as a key clinical target. The company is now investigating the impact that two of its ProTcell products in patients with severe combined immunodeficiency and leukemia could have.

Depiction of the thymus
The thymus produces all of the T-cells a person will need before they've even hit puberty • Source: 1200

“The thymus is absolutely instrumental in arming your T-cells to fight viruses and cancers,” said Smart Immune CEO Karine Rossignol. “If they don’t go into the thymus to be educated, they’re not efficient to protect you from cancers and infections. We have created this company to fight against both.”

An often-overlooked aspect of the lymphatic system, the thymus gland sits in the chest between the lungs and makes T-cells....

More from New Science

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.